CITISIGN P FORTE TAB - Dr Precision

CITISIGN P FORTE Tablet is a highly effective fixed-dose combination of Citicoline Sodium 500 mg and Piracetam 800 mg, formulated to deliver advanced neuroprotection and cognitive enhancement. This high-strength combination is used in the treatment and rehabilitation of patients suffering from neurological damage due to stroke, traumatic brain injury, Alzheimer’s disease, vascular dementia, and other cognitive and neurodegenerative conditions.

Citicoline Sodium is an intermediate in the biosynthesis of phosphatidylcholine, a major component of brain tissue. It plays a vital role in neuronal repair by promoting the synthesis of structural phospholipids in neuronal membranes. It also stimulates the production of neurotransmitters such as acetylcholine, dopamine, and norepinephrine, thereby restoring brain chemical balance after injury or degeneration. In several clinical studies, citicoline has demonstrated neuroprotective effects, especially in ischemic stroke, by improving cerebral blood flow, reducing infarct size, and accelerating recovery.

Piracetam, a cyclic derivative of GABA, is a well-established nootropic agent that enhances neuronal excitability, improves synaptic plasticity, and increases brain energy metabolism. It works by modulating ion channels and neurotransmission in the central nervous system, particularly enhancing learning and memory. Piracetam also improves microcirculation in the brain by reducing blood viscosity and improving erythrocyte flexibility, thus increasing oxygen and glucose delivery to neurons without causing vasodilation or sedation.

The CITISIGN P FORTE formulation provides a synergistic effect—Citicoline repairs damaged neurons and boosts neurotransmission, while Piracetam improves cerebral oxygenation and enhances neurocognitive performance. This dual-action makes the tablet particularly suitable for patients recovering from neurological trauma, ischemic stroke, or chronic neurodegenerative disorders where functional independence and cognitive improvement are therapeutic goals.

The formulation is especially beneficial in conditions such as:

Ischemic and hemorrhagic stroke

Alzheimer’s disease and other dementias

Post-traumatic brain injury

Cognitive impairment associated with age or vascular disease

Learning disabilities and attention disorders

Parkinsonian syndromes with cognitive decline